France Spent €13.5 Billion Making Its Medicines Cheap. That’s Now the Reason It Will Get the New Ones Last.

…The discipline that was meant to protect the health budget has quietly become the thing that starves it of innovation.

Since 2010, France has stripped roughly €13.5 billion out of the price of its medicines. Patiently, almost methodically — an average of €842 million a year, rising to €1.35 billion in 2025 alone, a 58% jump in twelve months — it has negotiated, clawed back, and cut, all to defend a health budget under permanent strain. It worked. France now has some of the lowest, most transparent medicine prices of any large market in Western Europe: by the industry’s own reckoning, around 11% below the European average for drugs without generic competition, and 16% below for those facing it.

That achievement is about to cost France the next generation of drugs.

Sixty-four per cent of the companies surveyed for the Leem’s 2026 attractiveness barometer — a group representing two-thirds of the industry’s French revenue — now expect to launch fewer new medicines in France over the next three years. Forty-seven per cent expect a sharp decline, seventeen per cent a moderate one. Not because France has grown poorer, or sicker, or less important — but because of a pricing policy being written in Washington. The discipline that was supposed to protect the French health budget has become the thing that will deprive it of innovation.

This is not the story of a country that became unattractive. It is the story of a country that optimised, brilliantly, for a world that has just ceased to exist.

For fifteen years, France ran one of the most effective cost-containment systems in Europe, and the numbers it produced were, on their own terms, a success. Beyond the €13.5 billion in cumulative price cuts, the safeguard clause — the macro clawback that activates when spending exceeds a ceiling — has settled at around €1.6 billion a year, roughly 6% of the industry’s French revenue. Effective taxation on the sector’s operating income reached 60% in 2023, of which 88% was specific to pharmaceuticals — against figures nearer 36% in Germany and 23% in Ireland. France learned, better than almost anyone, how to pay less for medicine.

What it bought with that discipline is the other half of the ledger, and it is less flattering. France is now the second-largest medicines market in Europe and one of the slowest to reach its patients. The median wait between European authorisation and actual availability hit 523 days in 2024 — the longest in Western Europe, and close to ten times Germany’s 50. The number of products stuck in price negotiation for more than 500 days rose 22% in a single year. Availability of recently approved medicines sits at 60%, against 89% in Germany. And the country that gave the world some of its foundational pharmaceutical science now manufactures barely 9% to 10% of the new drugs authorised in Europe, running a pharmaceutical trade surplus of €4 billion — beside Ireland’s €84 billion.

France pays the least and waits the longest. It always did. The difference is that the waiting is now about to get worse.

Because the same low, transparent price that looked like prudence has become, under a new American policy, a liability France cannot control.

The mechanism is the one we have traced across this series. The United States’ most-favoured-nation framework ties the price American payers pay to the lowest prices found in comparable developed markets. France, with prices among the lowest in Western Europe and a system built on published, referenceable tariffs, is close to an ideal anchor — exactly the kind of low number that, once visible, can be used to drag the American price down.

Which means a low French price is no longer a saving France quietly keeps. It is a signal France involuntarily exports.

For a manufacturer, the calculation that follows is brutally simple. A new medicine launched cheaply in France no longer just earns a thin French margin; it now risks compressing the far larger American one through MFN exposure. The rational response is to launch later in France, or in a narrower indication, or — for some products — not at all. Analysts have a name for it: “G7 Ghosting,” the deliberate delay of launches in high-income reference markets to avoid creating a low anchor. France, with the worst access delay in Western Europe and some of its lowest prices, is the textbook candidate. The 64% in the barometer are not speculating. They are describing their own launch plans.

A low price used to be a saving France kept. Under MFN, it is a signal France exports — and the export is now being priced in.

Here is what makes the French position different from its neighbours’, and far worse.

We have now watched three European answers to the same American pressure. Japan tried to install upward flexibility into a pricing system built only to cut, and discovered it had no reverse gear. Britain folded — raising its cost-effectiveness threshold by 25% and slashing its industry rebate as the price of a trade deal that kept tariffs off its exports. Germany is resisting, tightening its own controls, and has been rewarded with a formal US trade investigation for its trouble. Three countries, three strategies: adapt, capitulate, defy.

France can do none of them.

It cannot capitulate like Britain, because it has no fiscal room to spend its way to a deal: the entire apparatus of price cuts and clawbacks exists precisely because the budget cannot absorb more. It cannot comfortably defy like Germany, whose economy is large enough and whose surpluses are deep enough to take the fight. And it cannot, like Japan, simply legislate higher prices, because every euro added back is a euro the French health system does not have. France is caught in a vice it built itself: Washington pushing the price up, a cornered Treasury pushing it down, and a system that was already the slowest in Western Europe to deliver innovation.

Britain bought its way out. Germany can afford to fight. France can do neither.

And in that vice, the loser is the one who was already losing — the French patient, who waits 523 days today and will, on the industry’s own forecast, wait for fewer medicines tomorrow.

The French case is not a local curiosity. It is what happens when a successful cost-containment strategy meets a pricing regime it was never designed for. Four things follow.

First, for global launch teams, France has moved from a default mid-sequence market to a live strategic decision. The low published price that made France manageable is now an MFN exposure to be managed in its own right — through sequencing, through whatever confidentiality is achievable, through indication strategy. Treat the French launch as a question, not a formality.

Second, the squeeze is structural, not negotiable. Unlike Britain’s threshold or Germany’s resolve, France’s position is set by arithmetic: a health budget that cannot give, against an external pressure that will not. Expect the vice to persist across governments and PLFSS cycles, because none of them can change the underlying numbers without finding money that does not exist.

Third, transparency has become the exposed flank. France’s prices are an anchor precisely because they are visible and referenceable — and the barometer notes France is already pushing back on the perception that its prices sit below the European norm. Watch confidentiality become the battleground here, as it has in Germany: the value of a low price, to the system that sets it, now depends on whether the rest of the world can see it.

Fourth, and least comfortably: the patient pays twice. France already has the longest access delay in Western Europe and the lowest availability of any major market, and MFN hands manufacturers a fresh, rational reason to make both worse. The cost-containment that looked, for fifteen years, like sound stewardship is turning into a barrier to care — not because the policy changed, but because the world around it did.

For fifteen years, France optimised its pricing system to do one thing: pay less. It succeeded so completely that it now has the cheapest medicines and the slowest access of any large market in Western Europe. The world it built that system for — one where a low domestic price stayed domestic — has just disappeared. In the one that replaced it, France’s great achievement has become its great exposure.

It paid the least. It waited the longest. And it is now first in line to be skipped.

Share

Beyond Approval publishes weekly strategic intelligence on market access, HTA, pricing, and regulatory shifts that reshape how medicines reach patients.